Muchmore
Brian Muchmore, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20140271542 | GENETIC MARKER FOR PREDICTING PROGNOSIS IN PATIENTS INFECTED WITH HEPATITIS C VIRUS - The present invention provides methods and materials for predicting the clinical outcome of a hepatitis C virus (HCV) infection. In particular, the invention relates to methods and materials for predicating the ability of an individual to spontaneously clear a hepatitis C virus infection. It also relates to methods and materials useful for predicting the clinical response of an individual suffering from HCV infection to administration of a therapeutic treatment. Also provided are kits for predicting the ability of an individual to spontaneously clear an HCV infection, or spontaneously clear such an infection. The methods and rated kits disclosed herein can also be used to develop a treatment plan for an individual infected with HCV, or who is at risk for developing such an infection. | 09-18-2014 |
20150050640 | NOVEL INTERFERON-LAMBDA4 (IFNL4) PROTEIN, RELATED NUCLEIC ACID MOLECULES, AND USES THEREOF - The invention is related to identification of an interferon-analog (IFNL4) protein and genetic association with spontaneous clearance of HCV infection and response to treatment for HCV infection. | 02-19-2015 |
David C. Muchmore, Eugene, OR US
Patent application number | Description | Published |
---|---|---|
20130172342 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT - The present invention is directed to methods of treating diseases or conditions mediated by elevated persistent sodium channel, such as ocular disorders, pain, multiple sclerosis, and seizure disorders utilizing a compound of Formula I | 07-04-2013 |
David Charles Muchmore, Eugene, OR US
Patent application number | Description | Published |
---|---|---|
20130172389 | BENZIMIDAZOLE DERIVATIVES AS SELECTIVE BLOCKERS OF PERSISTENT SODIUM CURRENT - The present invention is directed to a compound of Formula I | 07-04-2013 |
Douglas Boyer Muchmore, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20130022592 | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme - Provided are methods for continuous subcutaneous insulin infusion (CSII) that employ a hyaluronan-degrading enzyme, including a recombinant human PH20 (rHuPH20). The methods can be used to more consistently control blood glucose during the course of CSII. The methods can be used to treat subjects having diabetes or other insulin-associated disease or condition. | 01-24-2013 |
Robert A. Muchmore, Dexter, MI US
Patent application number | Description | Published |
---|---|---|
20120085198 | SELECTABLE MASS FLYWHEEL - A selectable mass flywheel assembly for a powertrain of a motor vehicle includes a first mass and a second mass. The first mass is connected to a crankshaft of an engine and the second mass engages with a clutch to transfer torque from the engine to a transmission. The two masses are rotationally coupled to each other with a spring and damper assembly. The flywheel assembly further includes a locking mechanism that engages both masses during the startup of the engine to lock the two masses together to minimize the vibrations and pulsations in the powertrain during startup of the engine. | 04-12-2012 |